MAP3K5 and hepatocellular carcinoma: These include suppressing oncogenic hedgehog-GLI signaling in medulloblastoma cells [89,117], inhibiting NF-κB pathway signaling in myelodysplastic syndrome cells [84], activating the ASK1/Cyp-D mitochondrial pathway in hepatocellular carcinoma cells [92], promoting epithelial gene expression of BRD4 and MYC nuclear cofactors in pancreatic cells [88], disabling microtubules and thereby directly affecting mitotic spindle formation [83], and restoring immunogenic HLA class I surface gene expression on Merkel cell carcinoma cells [93].